{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fquadshot-news-podcast.simplecast.com%2Fepisodes%2F11182024-extended-benefit-4PREXe4W","width":444,"version":"1.0","type":"rich","title":"11.18.2024 - Extended Benefit","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/d4956b26-f7a3-4f47-a83d-9293649d65c8/ec08e780-4e06-4c01-8109-4e894d682296/qs_sqaure.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/084b97f5-6ef1-47dc-ae1d-07063c7992c0\" height=\"200\" width=\"100%\" title=\"11.18.2024 - Extended Benefit\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Check out this week's QuadCast as we highlight the oncologic benefit of extended nodal dissection for prostate cancer, the comparison of Durvalumab and Cetuximab in cisplatin-ineligible H&N cancer patients, the high incidence of psoriasis development on immunotherapy, and more."}